SINGAPORE, March 18, 2025 /PRNewswire/ — Singapore’s tourism and retail industries are undergoing a transformation, with Chinese tourists increasingly relying on digital platforms like Meituan Dianping and Xiaohongshu to plan their trips. Recognizing this shift, FY Ads—the leader in cross-border marketing and the official overseas partner of both Meituan Dianping and Xiaohongshu—partnered with the Singapore Chinese Chamber of Commerce & Industry (SCCCI) and Meituan Dianping to host an exclusive industry event aimed at helping local businesses capitalize on this opportunity.

A Landmark Event for Singapore Businesses

On February 26, 2025, business leaders from Singapore’s F&B, retail, and hospitality sectors gathered at the SCCIOB Theatre for an insightful session on how to leverage Meituan Dianping to attract and convert Chinese tourists into loyal customers. The event, featuring expert speakers and real-world case studies, provided attendees with actionable strategies to enhance their digital presence and drive foot traffic.

Key Takeaways from the Event

1. Why Digital Trust is Crucial for Chinese Consumers
FY Ads’ CEO Linda Chen emphasized that Chinese tourists prioritize online reviews and trusted digital platforms, with research showing that 92% of Chinese travelers rely on online recommendations before making travel decisions. Unlike Western travelers, they rarely make spontaneous decisions, instead relying on user-generated content and social proof from platforms like Meituan Dianping and Xiaohongshu.

2. The Power of Meituan Dianping in Influencing Chinese Tourists
Hana Zhang, Global Business Director at Meituan Dianping, shared exclusive insights into how over 80% of Chinese tourists research their travel destinations on Meituan Dianping before arrival. With millions of active users searching for dining, shopping, and lifestyle recommendations daily, businesses with optimized Meituan Dianping profiles enjoy significantly higher visibility and sales.

3. Proven Success Stories: How Singapore Brands Are Winning on Chinese Platforms
The event highlighted real-world success stories, featuring brands like Raffles Hotel, TWG Tea, Dian Xiao Er, and Song Fa Bak Kut Teh, which have successfully engaged Chinese tourists through Meituan Dianping. Many businesses have seen a 30-50% increase in foot traffic and revenue by using digital strategies tailored to the Chinese market.

4. A New Era for Singapore’s Tourism & Retail Sectors
As Chinese inbound tourism continues to grow in 2025, businesses that fail to establish a presence on key Chinese platforms risk missing out on a massive consumer base. The event made it clear that adapting to the digital habits of Chinese travelers is no longer optional—it’s essential for sustained growth.

Businesses that act early will gain a first-mover advantage, securing brand loyalty among Chinese tourists before competitors catch up.

FY Ads: The Leading Cross-Border Marketing Agency

As the leader in cross-border marketing and the official overseas partner of Meituan Dianping and Xiaohongshu, FY Ads stands out by offering exclusive access to insider platform analytics, direct integration capabilities, and customized marketing solutions that help businesses achieve measurable growth in the Chinese market. Unlike other agencies, FY Ads provides direct partnerships, exclusive insights, and proven strategies to ensure maximum visibility and engagement for businesses targeting Chinese consumers.

“Our goal is to bridge the gap between Singapore businesses and Chinese tourists through the platforms they trust most,” said Linda Chen, CEO of FY Ads. “By leveraging our partnerships with Meituan Dianping and Xiaohongshu, we empower businesses to increase visibility, engagement, and revenue in the Chinese market.”

The Future of Chinese Tourism in Singapore

With Chinese tourism on the rise, businesses must act now to establish a strong presence on Meituan Dianping and Xiaohongshu. Don’t wait—early adopters will gain the first-mover advantage in capturing this growing market. Those who embrace digital-first strategies tailored to Chinese consumers will dominate the post-pandemic tourism boom.

For companies looking to maximize their reach and revenue, FY Ads offers expert consultation and execution strategies tailored to these platforms. Now is the time to act—businesses that take initiative today will be at the forefront of the booming Chinese tourism market.

MELBOURNE, Australia and PORTO ALEGRE, Brazil, March 18, 2025 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the Brazilian Health Regulatory Agency (Agencia Nacional de Vigilancia Sanitaria or ‘ANVISA’) has approved Illuccix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection) the Company’s lead prostate cancer imaging agent. Illuccix® is the first and only PSMA-PET[1] prostate cancer imaging agent to receive full regulatory approval in Brazil.

Illuccix®, after radiolabeling with 68Ga, is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer:

• With suspected metastasis who are candidates for definitive initial therapy treatment, and
• With suspected recurrence based on an elevated specific antigen (PSA) level in the serum.

The marketing authorization is granted to Telix’s partner R2PHARMA, Brazil’s leading cold kit manufacturer, nuclear pharmacy and cyclotron network, and a subsidiary of GSH Corp Participações S.A. (Grupo GSH). Telix has provided Grupo GSH with an exclusive license to manufacture, distribute and market Illuccix® in Brazil[2].

PSMA-PET is a diagnostic technology demonstrated to detect advanced prostate cancer. ANVISA becomes the latest regulatory body worldwide to approve Illuccix®[3], which is already commercially available in Australia, Canada, New Zealand and the United States, and has recently been approved in the United Kingdom and in multiple countries within the European Economic Area (EEA).

Dr. Sérgio Altino de Almeida, nuclear medicine specialist, at Rede D’Or, the largest integrated healthcare network in Brazil said, “The ANVISA approval of Illuccix provides access to advanced prostate cancer imaging for men across Brazil, a large and rapidly growing market for gallium-68 based radiopharmaceuticals. The ‘cold kit’ format with generator-produced gallium will facilitate broad equity of access for men living with prostate cancer, regardless of whether they are based in regional, rural or metropolitan areas.”

JV to manufacture and distribute radiopharmaceuticals for clinical and commercial use in Brazil

Telix also announces a joint venture (JV) with R2PHARMA to commercialize and distribute Telix’s therapeutic and diagnostic radiopharmaceutical products in Brazil, building on the existing partnership established in 2019. The JV further strengthens this relationship with a commitment to jointly bring to market innovative and first-in-class therapeutic radiopharmaceuticals and imaging agents in Brazil.

The market for radiopharmaceuticals in Brazil is experiencing significant growth driven by the increasing prevalence of chronic diseases such as cancer, advancements in imaging technologies, and a growing senior population. Over the next decade, the Brazilian radiopharmaceuticals market is projected to reach US$330 million[4], with this growth supported by rising investments in the healthcare industry, public health awareness, and the introduction of new and advanced radiopharmaceuticals.

Under the agreement, Telix and R2PHARMA will establish a JV company in Brazil (Telix Innovations Brazil, Ltda.). Telix Innovations Brazil will hold the exclusive licence to commercialize and distribute Illuccix® as well as future product candidates from Telix’s industry-leading theranostic pipeline. Telix Innovations Brazil will leverage the local knowledge and expertise of R2PHARMA to obtain the necessary licenses and governmental authorizations in Brazil[5].

Raphaël Ortiz, CEO Telix International, added, “Telix is pleased to bring Illuccix to Brazil and Latin America, with this new imaging modality now recognized in leading clinical practice guidelines and already being adopted in other parts of the world. We would like to acknowledge our partner R2PHARMA for their commitment to gallium-based PSMA-PET and the hope this brings for men living with prostate cancer in Brazil. The JV takes our collaboration to the next stage with the aim to address unmet need for therapeutic and diagnostic radiopharmaceuticals across a range of disease areas.”

R2PHARMA Nuclear Medicine & Innovation Vice-President, Rafael Madke, continued, “We are delighted to have been granted this marketing authorization for Illuccix in Brazil. The combination of Telix’s innovative theranostic pipeline and R2PHARMA’s manufacturing and distribution capabilities will support widespread access for patients and physicians to Illuccix and future additional products that until now have not been available in Latin America.”

For more information visit: http://r2pharma.com.